Table 1.

Tumor-to-normal organ ratios using conventional radioimmunotherapy with 1.4 nmol 125I-BC8 Ab or PRIT with 111In-DOTA-biotin following BC8 antibody-SA (chemical conjugate) or BC8 scFv4SA fusion protein (1.4 or 2.8 nmol) 24 hours after the injection of radioactivity

OrganBC8 AbBC8 Ab-SABC8 scFv4SA (1.4 nmol)BC8 scFv4SA (2.8 nmol)
Blood0.78 ± 0.206.57 ± 2.3232.29 ± 10.5645.83 ± 21.41
Kidney0.84 ± 0.275.33 ± 2.881.57 ± 0.632.19 ± 0.33
Liver1.66 ± 0.5513.12 ± 9.417.17 ± 3.2114.76 ± 1.48
Lung2.43 ± 0.7016.48 ± 12.8522.54 ± 7.5124.36 ± 4.35
Muscle5.88 ± 3.72118.77 ± 92.4676.74 ± 19.7253.21 ± 19.45
Small intestine3.65 ± 1.0856.81 ± 48.5434.07 ± 11.0273.12 ± 59.93
Colon4.13 ± 1.1443.72 ± 32.3525.45 ± 14.9514.07 ± 8.10
Spleen2.79 ± 0.6925.30 ± 18.9110.99 ± 3.8823.59 ± 5.48
Stomach4.40 ± 1.3751.45 ± 40.2030.14 ± 11.0353.16 ± 20.90
  • NOTE: For pretargeting groups, CA (5.8 nmol) was delivered 20 hours after Ab-conjugate or fusion protein administration followed 4 hours later by 1.2 nmol 111In-biotin (50 μCi). Groups of five mice were used to generate mean values. Data were normalized for tissue weight and corrected for radioactive decay.